He Zhi-Cheng, Liu Qing, Yang Kai-Di, Chen Cong, Zhang Xiao-Ning, Wang Wen-Ying, Zeng Hui, Wang Bin, Liu Yu-Qi, Luo Min, Li Lei, Niu Qin, Lu Hui-Min, Luo Tao, Yao Xiao-Hong, Guo Hai-Tao, Ji Jia-Le, Cao Mian-Fu, Shi Yu, Ping Yi-Fang, Bian Xiu-Wu
Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University (Army Medical University) and Key Laboratory of Tumor Immunopathology, Ministry of Education of China, Chongqing, 400038, China.
Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University (Army Medical University) and Key Laboratory of Tumor Immunopathology, Ministry of Education of China, Chongqing, 400038, China; Department of Gastroenterology, Daping Hospital, Third Military Medical University (Army Medical University), Chongqing, 400038, China.
Cancer Lett. 2022 May 1;533:215605. doi: 10.1016/j.canlet.2022.215605. Epub 2022 Feb 24.
Although the tumorigenic potential of glioma stem cells (GSCs) is associated with multiple molecular alterations, the gene amplification status of GSCs has not been elucidated. Overexpression of HomeoboxA5 (HOXA5) is associated with increased glioma malignancy. In this study, we identify the gene amplification and protein overexpression of HOXA5 in GSCs and its function in regulating GSC maintenance and the downstream transcriptional effector, to explore the significance of HOXA5 amplification/overexpression for GSC identification and prognostic determination. The HOXA5 gene is significantly amplified in glioblastoma (GBM) and is an independent prognostic factor for predicting worse patient outcomes. Specifically, HOXA5 gene amplification and the resultant protein overexpression are correlated with increased proportions of GSCs and enhanced self-renewal/invasiveness of these cells. Disruption of HOXA5 expression impairs GSC survival and GBM tumor propagation. Mechanistically, HOXA5 directly binds to the promoter region of protein tyrosine phosphatase receptor type Z1 (PTPRZ1), thereby upregulating this gene for GSC maintenance. Suppression of PTPRZ1 largely compromises the pro-tumoral effect of HOXA5 on GSCs. In summary, HOXA5 amplification serves as a genetic biomarker for predicting worse GBM outcome, by enhancing PTPRZ1-mediated GSC survival.
尽管胶质瘤干细胞(GSCs)的致瘤潜力与多种分子改变有关,但GSCs的基因扩增状态尚未阐明。同源盒A5(HOXA5)的过表达与胶质瘤恶性程度增加有关。在本研究中,我们鉴定了GSCs中HOXA5的基因扩增和蛋白过表达及其在调节GSC维持和下游转录效应因子方面的功能,以探讨HOXA5扩增/过表达对GSC鉴定和预后判定的意义。HOXA5基因在胶质母细胞瘤(GBM)中显著扩增,是预测患者预后较差的独立预后因素。具体而言,HOXA5基因扩增及由此产生的蛋白过表达与GSCs比例增加以及这些细胞的自我更新/侵袭能力增强相关。HOXA5表达的破坏损害了GSC存活和GBM肿瘤增殖。机制上,HOXA5直接结合蛋白酪氨酸磷酸酶受体Z1型(PTPRZ1)的启动子区域,从而上调该基因以维持GSC。抑制PTPRZ1在很大程度上损害了HOXA5对GSCs的促肿瘤作用。总之,HOXA5扩增通过增强PTPRZ1介导的GSC存活,作为预测GBM预后较差的遗传生物标志物。